Thrombocytopenia associated with sodium valproate treatment

Authors

  • Dr. Andreas N. Neophytides MD,

    Corresponding author
    1. Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD
    2. Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, MD
    • Department of Neurology, Veterans Administration Hospital, First Ave at E 24th St, New York, NY 10010
    Search for more papers by this author
  • John G. Nutt MD,

    1. Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD
    2. Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Jules R. Lodish MD

    1. Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD
    2. Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, MD
    Search for more papers by this author

Abstract

The administration of sodium valproate to 30 patients in daily doses of 1,200 to 3,000 mg was associated with a significant reduction of the platelet count. Thrombocytopenia without any concomitant bleeding abnormalities occurred in 10 of the patients. Platelet counts returned to baseline levels after withdrawal of the drug.

Ancillary